Biogen Response to the Charities' August 28th Joint Letter

09 October 2018

In our letter, we urged both Biogen and NHS England to be as flexible as possible in their discussion on the price of nusinersen. This is so that, as a matter of urgency, a Managed Access Agreement (MAA) that merges seamlessly with the current EAP is set up and ensures that all others are also able to access nusinersen at the earliest possible opportunity.

Read their reply